Cormorant Asset Management’s Atara Biotherapeutics ATRA Stock Holding History

Cormorant Asset Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-12,000	Closed	-$4.24M	–	71
2019 Q3	$4.24M	Sell	12,000 -4,000	-25%	-$1.49M	0.26%	58
2019 Q2	$8.04M	Sell	16,000 -6,000	-27%	-$4.24M	0.46%	54
2019 Q1	$21.9M	Buy	+22,000	New	+$20.4M	1.48%	26
2016 Q4	–	Sell	-7,458	Closed	-$3.99M	–	80
2016 Q3	$3.99M	Hold	7,458	–	–	0.44%	57
2016 Q2	$4.2M	Buy	7,458 +1,458	+24%	+$700K	0.6%	47
2016 Q1	$2.85M	Hold	6,000	–	–	0.43%	55
2015 Q4	$3.96M	Hold	6,000	–	–	0.47%	50
2015 Q3	$4.72M	Buy	6,000 +4,000	+200%	+$4.88M	0.75%	38
2015 Q2	$2.64M	Buy	+2,000	New	+$2.29M	0.35%	56

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Cormorant Asset Management's ATRA Position: Q4 2019 in Review

Cormorant Asset Management sold out of Atara Biotherapeutics (ATRA) in Q4 2019, closing a stake of 12,000 shares — an estimated $4.24M sold.

Cormorant Asset Management first reported a position in ATRA in Q2 2015 and held it in 9 quarters. The position peaked at $21.9M in Q1 2019. 117 funds tracked by Wall St. Rank hold ATRA as of Q4 2019.

Cormorant Asset Management reported no remaining Atara Biotherapeutics position as of Q4 2019 after selling out during the quarter.
Cormorant Asset Management sold 12,000 Atara Biotherapeutics shares in Q4 2019, an estimated $4.24M.
Cormorant Asset Management first reported a position in Atara Biotherapeutics in Q2 2015 and held it in 9 quarters.
Cormorant Asset Management's Atara Biotherapeutics position peaked at $21.9M in Q1 2019.
117 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2019.

Based on Cormorant Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.